SCHEMBL4078135

SCHEMBL4078135

ON(O)C1CCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19940652 0.96 PHGDH (0.42)
SCHEMBL9009900 0.96
SCHEMBL14733936 0.84
SCHEMBL15234029 0.81 ADH1A (0.32)
SCHEMBL2140852 0.77 ADH1A (0.38)
SCHEMBL1170432 0.74 PHGDH (0.42)
SCHEMBL9930440 0.72 ADH1A (0.35)
SCHEMBL14960417 0.72
SCHEMBL3585841 0.69
SCHEMBL8011374 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1175420-B1 PROCESS FOR PREPARING N6-SUBSTITUTED DEAZA-ADENOSINE DERIVATIVES AVENTIS PHARMA INC (US) 2003-03-26 EP claimed
EP-1175420-A2 PROCESS FOR PREPARING N6-SUBSTITUTED DEAZA-ADENOSINE DERIVATIVES Aventis Pharmaceuticals Products Inc. (US) 2002-01-30 EP claimed
US-6184382-B1 4-(7-((1-((3-CHLOROTHIEN-2-YL)METHYL)PROPYL)AMINO)-3H-IMIDAZO (4, 5-B)PYRID-3-YL) N-ETHYL-2,3-DIHYDROXYCYCLOPENTANECARBOXAMIDE ARE USEFUL AS CARDIOVASCULAR AGENTS, ANTIHYPERTENSIVE, ANTI-ISCHEMIC AGENTS, AVENTIS PHARMACEUTICALS PRODUCTS INC. 2001-02-06 US claimed
WO-2000037469-A2 PROCESS FOR PREPARING N6-SUBSTITUTED DEAZA-ADENOSINE DERIVATIVES AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-06-29 WO claimed
US-7598252-B2 Compounds specific to adenosine A, receptors and uses thereof OSI PHARMACEUTICALS, INC. (US) 2009-10-06 US disclosed
US-20090082369-A1 Pyrrolo[2,3d]pyrimidine compositions and their use OSI PHARMACEUTICALS, INC. 2009-03-26 US disclosed
EP-2011499-A2 Pyrrolo[2,3d]Pyrimidine compositions and their use OSI Pharmaceuticals, Inc. (US) 2009-01-07 EP disclosed
US-7429574-B2 4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and their use OSI PHARMACEUTICALS, INC. (US) 2008-09-30 US disclosed
US-7417153-B2 Method for the production of 3-amino-5-(hydroxymethyl)cyclopentane-1,2-diol derivatives LONZA AG (CH) 2008-08-26 US disclosed
US-20080070936-A1 Compounds specific to adenosine A1 receptors and uses thereof OSI PHARMACEUTICALS, INC. 2008-03-20 US disclosed
EP-1771434-A2 METHOD FOR THE PRODUCTION OF 3-AMINO-5-(HYDROXYMETHYL)CYCLOPENTANE-1,2-DIOL DERIVATIVES LONZA AG (CH) 2007-04-11 EP disclosed
CN-1922166-A Process for producing 3-amino-5- (hydroxymethyl) cyclopentane-1, 2-diol derivative LONZA AG (CH) 2007-02-28 CN disclosed
US-6429315-B1 CYCLIZATION BY REACTION WITH FORMIC ACID DERIVATIVE; DEBLOCKING, DEPROTECTION AVENTIS PHARMACEUTICALS INC. 2002-08-06 US disclosed
EP-1175420-A2 PROCESS FOR PREPARING N6-SUBSTITUTED DEAZA-ADENOSINE DERIVATIVES Aventis Pharmaceuticals Products Inc. (US) 2002-01-30 EP disclosed
EP-1140933-A2 PROCESS FOR PREPARING N6-SUBSTITUTED DEAZA-ADENOSINE DERIVATIVES Aventis Pharmacueticals Products Inc. (US) 2001-10-10 EP disclosed
EP-1082120-A1 PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE OSI Pharmaceuticals, Inc. (US) 2001-03-14 EP disclosed
US-6184382-B1 4-(7-((1-((3-CHLOROTHIEN-2-YL)METHYL)PROPYL)AMINO)-3H-IMIDAZO (4, 5-B)PYRID-3-YL) N-ETHYL-2,3-DIHYDROXYCYCLOPENTANECARBOXAMIDE ARE USEFUL AS CARDIOVASCULAR AGENTS, ANTIHYPERTENSIVE, ANTI-ISCHEMIC AGENTS, AVENTIS PHARMACEUTICALS PRODUCTS INC. 2001-02-06 US disclosed
WO-2000040584-A2 PROCESS FOR PREPARING N6-SUBSTITUTED DEAZA-ADENOSINE DERIVATIVES AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-07-13 WO disclosed
WO-2000037469-A2 PROCESS FOR PREPARING N6-SUBSTITUTED DEAZA-ADENOSINE DERIVATIVES AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-06-29 WO disclosed
WO-1999062518-A1 PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE OSI PHARMACEUTICALS, INC. (US) 1999-12-09 WO disclosed